Patents by Inventor George Jackowski

George Jackowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Apolipoprotein biopolymer markers indicative of insulin resistance
    Patent number: 7314762
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or the absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: January 1, 2008
    Assignee: Nanogen, Inc.
    Inventors: George Jackowski, John Marshall
  • Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
    Patent number: 7314717
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: January 1, 2008
    Assignee: Nanogen Inc.
    Inventors: George Jackowski, Brad Thatcher, John Marshall, Jason Yantha, Tammy Vrees
  • Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
    Patent number: 7294688
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: November 13, 2007
    Assignee: Nanogen Inc.
    Inventors: George Jackowski, Brad Thatcher, John Marshall, Jason Yantha, Tammy Vrees
  • APOLIPOPROTEIN BIOPOLYMER MARKERS INDICATIVE OF INSULIN RESISTANCE
    Publication number: 20070190666
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
    Type: Application
    Filed: November 21, 2001
    Publication date: August 16, 2007
    Inventors: George Jackowski, John Marshall
  • Methods for predicting outcome in traumatic brain injury
    Publication number: 20070184507
    Abstract: The invention describes methods for predicting outcome for patients suffering from traumatic brain injury (TBI) by evaluating levels of markers commonly associated with cellular damage in bodily fluids. Utilization of such methods improves diagnosis and treatment of patients suffering from traumatic brain injury, thus potentially minimizing and/or eliminating long-term adverse effects in these patients.
    Type: Application
    Filed: April 19, 2007
    Publication date: August 9, 2007
    Inventors: George Jackowski, Eric Stanton, Petro Kupchak, Miyoko Takahashi, Michelle Davey
  • Biopolymer marker indicative of disease state having a molecular weight of 1525 Daltons
    Patent number: 7229638
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of a biopolymer.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: June 12, 2007
    Assignee: Artemis Proteomics, Ltd.
    Inventors: George Jackowski, Brad Thatcher, John Marshall, Jason Yantha, Tammy Vrees
  • Fibronectin precursor biopolymer markers indicative of alzheimer's disease
    Patent number: 7179605
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
    Type: Grant
    Filed: November 23, 2001
    Date of Patent: February 20, 2007
    Assignee: Nanogen Inc.
    Inventors: George Jackowski, John Marshall
  • Complement C3 precursor biopolymer markers indicative of insulin resistance
    Patent number: 7179610
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
    Type: Grant
    Filed: November 23, 2001
    Date of Patent: February 20, 2007
    Assignee: Nanogen Inc.
    Inventors: George Jackowski, John Marshall
  • IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
    Patent number: 7179606
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
    Type: Grant
    Filed: November 23, 2001
    Date of Patent: February 20, 2007
    Assignee: Syn X Pharma, Inc.
    Inventors: George Jackowski, John Marshall
  • Protein biopolymer markers predictive of type II diabetes
    Publication number: 20070031979
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
    Type: Application
    Filed: October 12, 2006
    Publication date: February 8, 2007
    Inventors: George Jackowski, John Marshall
  • Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
    Publication number: 20070020769
    Abstract: An immunochemical assay device for determining the presence of NT-proBNP alone or conjunctively with Cardiac Troponin I comprising a base member, an array disposed on the base member, and at least one assay indicia zone. The array comprises (i) a reservoir pad to receive sample liquid, (ii) a wicking membrane, and (iii) at least one filter zone interposed between the wicking membrane and the reservoir pad. The filter zone being operable to permit passage of any specific immunocomplex to the wicking membrane while impeding passage of larger components.
    Type: Application
    Filed: September 28, 2006
    Publication date: January 25, 2007
    Applicant: Princeton Biomeditech Corporation
    Inventors: Jemo Kang, Kyung-ah Kim, Joo Young Choi, George Jackowski
  • Apolipoprotein biopolymer marker indicative of normal human
    Publication number: 20070009963
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
    Type: Application
    Filed: September 7, 2006
    Publication date: January 11, 2007
    Inventors: George Jackowski, John Marshall
  • Protein biopolymer markers predictive of insulin resistance
    Publication number: 20070010029
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative-to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
    Type: Application
    Filed: September 7, 2006
    Publication date: January 11, 2007
    Inventors: George Jackowski, John Marshall
  • Complement C3 precursor biopolymer markers indicative of insulin resistance
    Publication number: 20070010030
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
    Type: Application
    Filed: September 7, 2006
    Publication date: January 11, 2007
    Inventors: George Jackowski, John Marshall
  • Cene-E biopolymer marker indicative of age matched control
    Publication number: 20070003974
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
    Type: Application
    Filed: November 23, 2001
    Publication date: January 4, 2007
    Inventors: George Jackowski, John Marshall
  • Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons
    Publication number: 20060292703
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.
    Type: Application
    Filed: July 13, 2006
    Publication date: December 28, 2006
    Inventors: George Jackowski, Brad Thatcher, John Marshall, Jason Yantha, Tammy Vrees
  • Complement C3 precursor biopolymer markers predictive of type II diabetes
    Publication number: 20060275831
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
    Type: Application
    Filed: August 14, 2006
    Publication date: December 7, 2006
    Inventors: George Jackowski, John Marshall
  • Protein biopolymer markers indicative of insulin resistance
    Patent number: 7135297
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against disease.
    Type: Grant
    Filed: November 23, 2001
    Date of Patent: November 14, 2006
    Assignee: Nanogen Inc.
    Inventors: George Jackowski, John Marshall
  • Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
    Patent number: 7135329
    Abstract: An immunochemical assay device for determining the presence of NT-proBNP alone or conjunctively with Cardiac Troponin I comprising a base member, an array disposed on the base member, and at least one assay indicia zone. The array comprises (i) a reservoir pad to receive sample liquid, (ii) a wicking membrane, and (iii) at least one filter zone interposed between the wicking membrane and the reservoir pad. The filter zone being operable to permit passage of any specific immunocomplex to the wicking membrane while impeding passage of larger components.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: November 14, 2006
    Assignee: Princeton Biomeditech Corporation
    Inventors: Jemo Kang, Kyung-ah Kim, Joo Young Choi, George Jackowski
  • Conjunctive analysis of biological marker expression for predicting cardiac mortality
    Patent number: RE39816
    Abstract: A diagnostic tool is disclosed for accurately and rapidly diagnosing the condition of an ailing organ. Although applicable to numerous organ and organ systems, this application particularly illustrates the concept of conjunctive marker utilization as it relates to diagnosing and distinguishing congestive heart failure. The invention particularly relates to the conjunctive utilization of cardiac Troponin I (cTn-I) and natriuretic peptide, e.g. ANP, pro-ANP, BNP, pro-BNP and CNP as a retrospective tool for diagnosing the underlying mechanism of heart failure and as a prospective analytical device for monitoring disease progression and efficacy of therapeutic agents.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: September 4, 2007
    Assignee: Nanogen Inc.
    Inventors: Eric B. Stanton, George Jackowski